Praxis Precision Medicines (NASDAQ:PRAX) Upgraded by Wall Street Zen to "Hold" Rating

Key Points

• Wall Street Zen upgraded Praxis Precision Medicines to “Hold” from “Sell,” although the broader analyst consensus remains “Buy,” with an average price target of $573.05.
• PRAX reported a second-quarter loss of $2.87 per share, beating the $3.67 consensus estimate. Needham maintained its “Buy” rating and raised its price target to $582.
• Shares opened at $360.76, near their 52-week high, while the company remains unprofitable and expects a full-year loss; investors are also awaiting potential FDA decisions for its pipeline and may face valuation-related volatility.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.

PRAX has been the topic of several other reports. Truist Financial set a $616.00 price objective on shares of Praxis Precision Medicines and gave the stock a "buy" rating in a research report on Tuesday, June 2nd. Raymond James Financial began coverage on shares of Praxis Precision Medicines in a research report on Friday, April 10th. They set a "strong-buy" rating and a $815.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Praxis Precision Medicines in a report on Wednesday, May 27th. Oppenheimer reaffirmed an "outperform" rating and set a $650.00 price target (down from $750.00) on shares of Praxis Precision Medicines in a research report on Tuesday, June 2nd. Finally, Needham & Company LLC lifted their price target on Praxis Precision Medicines from $575.00 to $582.00 and gave the stock a "buy" rating in a report on Thursday. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, Praxis Precision Medicines has an average rating of "Buy" and an average target price of $573.05.

Praxis Precision Medicines Price Performance

PRAX opened at $360.76 on Friday. The company has a market capitalization of $10.06 billion, a price-to-earnings ratio of -27.90 and a beta of 2.78. The firm's fifty day moving average price is $303.99 and its two-hundred day moving average price is $315.79. Praxis Precision Medicines has a 1 year low of $37.19 and a 1 year high of $382.54.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($2.87) EPS for the quarter, beating the consensus estimate of ($3.67) by $0.80. As a group, equities analysts anticipate that Praxis Precision Medicines will post -14.82 EPS for the current year.

Insider Buying and Selling

In other Praxis Precision Medicines news, Director Jill Desimone sold 11,600 shares of Praxis Precision Medicines stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $311.32, for a total value of $3,611,312.00. Following the sale, the director owned 2,337 shares of the company's stock, valued at approximately $727,554.84. The trade was a 83.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.00% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PRAX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Praxis Precision Medicines by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,708 shares of the company's stock worth $444,000 after purchasing an additional 573 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Praxis Precision Medicines by 367.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 87,081 shares of the company's stock valued at $3,298,000 after purchasing an additional 68,466 shares during the last quarter. Creative Planning purchased a new position in Praxis Precision Medicines in the second quarter valued at approximately $273,000. JPMorgan Chase & Co. grew its holdings in Praxis Precision Medicines by 21.4% during the second quarter. JPMorgan Chase & Co. now owns 13,938 shares of the company's stock valued at $586,000 after purchasing an additional 2,459 shares during the period. Finally, Legal & General Group Plc grew its holdings in Praxis Precision Medicines by 15.7% during the second quarter. Legal & General Group Plc now owns 16,670 shares of the company's stock valued at $701,000 after purchasing an additional 2,261 shares during the period. 67.84% of the stock is owned by institutional investors.

Trending Headlines about Praxis Precision Medicines

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: Praxis said it expects two FDA decisions within roughly six months and is targeting approximately $10 billion in peak sales for ulixacaltamide. The company is also preparing a commercial organization of about 300 field employees, signaling confidence in the drug’s market potential. Praxis signals two FDA decisions and targets $10 billion in peak sales
• Positive Sentiment: Management’s planned commercial launch could exceed expectations if regulatory approvals are secured and adoption develops as projected, strengthening the long-term growth narrative for PRAX. Praxis commercial launch could smash expectations
• Positive Sentiment: Praxis reported a second-quarter loss of $2.87 per share, narrower than the $3.67 analyst consensus, providing a better-than-expected earnings result. Needham & Company also raised its price target from $575 to $582 and maintained a Buy rating. Needham raises Praxis price target Praxis corporate update and second-quarter results
• Neutral Sentiment: The company remains unprofitable and expects a full-year loss, while building a sizeable commercial infrastructure ahead of potential approvals. Those investments could increase expenses before product revenue begins.
• Negative Sentiment: With PRAX near its 52-week high, a market capitalization above $10 billion, and a high beta, the stock is vulnerable to valuation-driven profit-taking. Investors may also be locking in gains while awaiting the FDA decisions and clearer evidence of launch execution.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company's pipeline includes several lead candidates at various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source